All In Biotech

Drug Trial Radar · NCT05465681

Study of HR20013 for Injection in Patients With Malignant Solid Tumors

A Phase I Clinical Study of Safety and Pharmacokinetics of Single-dose HR20013 for Injection Combined With Dexamethasone in Patients With Malignant Solid Tumors Receiving Cisplatin-based Chemotherapy

Last checked: Nov 19, 2026Latest source record: Apr 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Aug 30, 2022

Primary completion

Jan 13, 2023

Study completion Jan 13, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and pharmacokinetics of single-dose HR20013 for injection combined with dexamethasone in patients with malignant solid tumors receiving cisplatin-based chemotherapy.

Conditions

  • Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy

Interventions

  • HR20013 for injection;dexamethasonDrug

    HR20013 for injection;Drug for preventing nausea and vomiting caused by chemotherapy. dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC0-t :area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentrationTime frame: 0 to 504 hours
  2. AUC0-∞:Area Under the Plasma Concentration-time Curve From Time 0 to InfinityTime frame: 0 to 504 hours
  3. Cmax:observed maximum plasma concentrationTime frame: 0 to 504 hours
  4. Tmax:observed time to reach CmaxTime frame: 0 to 504 hours
  5. T1/2z:apparent terminal half-lifeTime frame: 0 to 504 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.